Literature DB >> 1551001

The role of immunization treatment in preventing recurrent abortion.

A M Unander1.   

Abstract

Published reports of controlled studies of immunization treatment in recurrent abortion have not shown any ability of either third-party cells or the husband's cells to prevent further abortions, whereas preliminary results of ongoing studies speak in favor of a beneficial effect of third-party cells. However, the lack of significant differences so far does not prove that immunotherapy in habitual abortion is ineffective, because all of these studies include too few patients in each group to give any conclusive results. Only a mega-trial could evaluate the efficacy and side effects of leukocyte immunotherapy. Such controlled studies are needed to clarify the true benefits, risks, and limitations of immunization treatment in recurrent abortion. Factors such as appropriate inclusion criteria, the time relationship between immunization and the next pregnancy, the number of immunizations required, the cell source and cell doses need to be established. Until this additional information is available this treatment should not be considered routinely indicated. This approach should be restricted to a few centers in order to provide maximal possibilities for collection and evaluation of the data.

Entities:  

Mesh:

Year:  1992        PMID: 1551001     DOI: 10.1016/s0887-7963(92)70151-5

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  3 in total

Review 1.  Intravenous immune globulin in recurrent abortion.

Authors:  O Heine; G Mueller-Eckhardt
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

2.  Transfusion-associated immunomodulation: Quantitative changes in cytokines as a measure of immune responsiveness after one time blood transfusion in neurosurgery patients.

Authors:  Prashant Pandey; Rajendra Chaudhary; Amita Aggarwal; Raj Kumar; Dheeraj Khetan; Anupam Verma
Journal:  Asian J Transfus Sci       Date:  2010-07

Review 3.  Age of blood: does it make a difference?

Authors:  Patrick J Offner
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.